SOD1 and amyotrophic lateral sclerosis: Sephin1, also named icerguastat or IFB-088, which has completed a phase 2 clinical trial in bulbar-onset ALS patients (NCT05508074), has been previously evaluated in SOD1G93A mice showing beneficial effects, including improvement of motor neuron survival and decrease of SOD1 aggregates (Das et al, 2015; Vieira et al, 2024).